News

Brain Stimulation Bests Medical Therapy for PD


 

Dr. Rodriguez-Oroz of the Clinica Universidad de Navarra, Pamplona, Spain, added that some limitations of the trial raise questions about the results. For example, neither patients nor evaluators were masked to treatment. Evaluations of dyskinesia and “off” period time could have been done with a more reliable tool than the complications of therapy subsection of the UPDRS. Investigators made their own judgment about whether a patient was in the “on” state (without assessment of inter-rater reliability). The DRS-II might be inadequate to assess cognitive ability in Parkinson's. And the investigators did not record nonserious adverse events.

Pages

Recommended Reading

Cilostazol Beats Aspirin for Stroke Prevention
MDedge Internal Medicine
Arm Rehab Boosts Function in Chronic Stroke
MDedge Internal Medicine
Increase Seen in Percentage of Stroke Patients Under Age 45
MDedge Internal Medicine
Alzheimer's More Common in Blacks, Hispanics
MDedge Internal Medicine
Dietary Pattern Linked to Risk for Alzheimer's Disease
MDedge Internal Medicine
Hypertension-Dementia Link in Some With MCI
MDedge Internal Medicine
Anticonvulsant Warning Led to Decreased Use
MDedge Internal Medicine
Memantine ER Seems Safe and Well Tolerated
MDedge Internal Medicine
Study Links Four Anticonvulsants to Suicide Risk
MDedge Internal Medicine
Guidance Is Sparse for Nonmotor PD Symptoms
MDedge Internal Medicine